Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and ...

Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

The research reveals that dronedarone, previously used for atrial fibrillation, could significantly suppress ESCC cell growth by targeting the CDK4/6-RB1 pathway, a key regulator of the cell cycle ...

The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb.

The combination also demonstrated a consistent PFS benefit across other key subgroups, including patients who received prior treatment with CDK4/6 inhibitors, and those with PI3K pathway mutations.

Dysregulation of this pathway is implicated in the progression of various cancers ... Proteomic Profiling Predicts Response to CDK4/6 inhibitors: Patients with an activated AKT–mTOR signaling axis ...

Dysregulation of this pathway is implicated in the progression ... Proteomic Profiling Predicts Response to CDK4/6 inhibitors: Patients with an activated AKT–mTOR signaling axis showed worse ...